# Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors

> **NCT01381822** · PHASE1 · UNKNOWN · sponsor: **Threshold Pharmaceuticals** · enrollment: 58 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma
- Gastrointestinal Stromal Tumors
- Pancreatic Neuroendocrine Tumors

## Interventions

- **DRUG:** TH-302

## Key facts

- **NCT ID:** NCT01381822
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-06
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381822, "Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01381822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*